Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
AngioDynamics (ANGO) exceeds expectations, raises guidance for fiscal 2026 with positive cash flow expected.
Canaccord Genuity analyst William Plovanic maintains AngioDynamics (NASDAQ:ANGO) with a Buy and raises the price target from...
U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining around 0.2% on Thursday. The Dow trade...
Shares of AngioDynamics, Inc. (NASDAQ: ANGO) are up Thursday after the biotechnology company raised guidance for four key finan...
AngioDynamics (NASDAQ:ANGO) raises FY2026 Adj EPS guidance from $(0.35)-$(0.25) to $(0.33)-$(0.23) vs $(0.31) analyst estimate....
AngioDynamics (NASDAQ:ANGO) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.12)...
U.S. stock futures were fluctuating on Thursday following Wednesday's record advances. Futures of major benchmark indices w...
CNN Business Fear & Greed Index at 52.3, remaining in Neutral zone. Stocks close higher despite economic headwinds, with re...
